62 citations
,
January 2004 in “PubMed” 5alpha-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT, offering symptom relief and potential future uses.
Encapsulating hair loss drugs in cyclodextrins improves their solubility and reduces scalp irritation.
3 citations
,
February 2021 in “The Journal of Urology” Dutasteride can reduce night-time urination but it doesn't improve sleep quality.
January 2025 in “Organics” Micelles can change cetirizine's ionization, affecting its effectiveness in treatments.
27 citations
,
May 2016 in “Integrative Cancer Therapies” Chrysin makes docetaxel more effective and reduces its side effects in lung cancer treatment.
7 citations
,
July 1995 in “PubMed” Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.
13 citations
,
January 1987 in “Dermatology” Minoxidil sulfate relaxes blood vessels by increasing potassium permeability.
1 citations
,
June 2023 in “Frontiers in Pharmacology” Vasodilators may worsen abdominal aortic aneurysm.
8 citations
,
October 2016 in “Journal of Investigative Dermatology” MR antagonists may improve skin health and wound healing, especially in aging.
January 2012 in “Земский врач” Finasteride helps improve treatment for benign prostatic hyperplasia.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
10 citations
,
July 2011 in “Archives of Pharmacal Research”
Blocking 11β-HSD1 reduces stress hormone damage in hair growth cells.
January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
December 2024 in “ACS Applied Materials & Interfaces” The new hydrogel helps heal diabetic wounds by reducing inflammation and improving tissue repair.
August 1978 in “Dicp-The annals of pharmacotherapy” Mannitol diuresis allows higher doses of cis-platinum for testicular cancer treatment without increasing kidney damage.
2 citations
,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
12 citations
,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
January 2018 in “Haydarpaşa Numune Hastanesi tıp dergisi” Tamsulosin's sulfonamide group may contribute to floppy iris syndrome.
58 citations
,
March 2006 in “Current topics in medicinal chemistry” Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
8 citations
,
May 2020 in “Arthritis research & therapy” DHT inhibition may increase spinal bone growth in ankylosing spondylitis.
17 citations
,
August 2011 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.
March 2009 in “The Journal of Urology” Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.
44 citations
,
January 2012 in “Food and chemical toxicology” Ursolic acid can shrink the prostate and lower a hormone linked to prostate growth in rats.
23 citations
,
January 1998 in “Urological research” Castration and finasteride lower urinary oxalate in male rats, potentially treating urolithiasis.
January 2014 in “Shiyong laonian yixue” Tamsulosin and finasteride improve heart function and circadian rhythm in elderly men with heart failure and prostate issues.
21 citations
,
April 2018 in “The Journal of urology/The journal of urology” SER120 nasal spray effectively reduces nighttime urination and is safe for patients.
13 citations
,
January 2015 in “Molecular Pharmaceutics” Minoxidil works well as a high permeability reference drug for biopharmaceutics classification.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
8 citations
,
October 2024 in “Cochrane Database of Systematic Reviews” Tolvaptan can slow kidney disease progression, but doesn't affect mortality or kidney failure.